Health Equity Promise and That Innovation Thing

President Biden has pledged his administration to defeat cancer, Alzheimer’s, and other diseases that target America’s aging population. To achieve these lofty goals, bold words must be backed up by bold actions. Yet, many of the administration’s proposed policies will cripple the one indispensable weapon in the battle to conquer disease — medical innovation.

By 2025, 73 million U.S. baby boomers will be age 60 or older. Within the baby boomer generation are countless examples of how medical innovation has enabled people with HIV, Osteoporosis, CVD, and other health conditions to survive and thrive.

Though they might not intend it, the Biden administration seems committed to fighting tomorrow’s battles with yesterday’s medicines rather than encouraging the next generation of innovation. Imagine trying to address climate change without promoting progress in electric vehicles and battery technology. Accepting the old landline as “good enough” and spurning the life-improving advances in mobile technologies or telling us boomers to keep our old Trinitron TVs and forget 21st-century flat-screen innovation.

Consider drug price “negotiation,” which is simply Washington-speak for allowing the government to set prices in Medicare. The result would be fewer drug choices, limiting patients’ access to the most effective medicines to treat their chronic illnesses and stifling future drug innovation. Does anyone really believe this is the path to conquering cancer or Alzheimer’s?

Voters understand the political bait-and-switch. Nearly two-thirds (65 percent) of Americans oppose drug price “negotiation” if it could lead to less research and development of new treatments or limit access to medicines.

Americans also recognize that the anti-viral therapies and vaccines used to treat chronic conditions like COVID-19, HIV, and cancer would not exist today without deep investments and intellectual property protections that enable biomedical innovation.

Government-controlled drug prices are not only at odds with President Biden’s commitment to defeating difficult diseases but also fly in the face of efforts to close gaps in health care access for underserved communities and improve equity in our country.

CMS has encouraged leaders in the healthcare industry to make commitments and suggestions toward a national strategy to advance health equity. As these individuals contribute their ideas, they must consider the need for this strategy to include America’s aging communities, given that innovation is an essential element of a healthier aging community. We must ensure that seniors have access to the treatments and cures they need through access to existing treatments and the protection of future research and development efforts.

Americans have come to expect innovation in nearly every area of life. We should not accept anything less in health and medical innovation.

Instead of dead-end policies like putting bureaucrats in charge of drug prices, Washington should treat innovation as an investment in our aging communities that can improve the health of older Americans and avoid greater healthcare spending in the future. Support from the Biden administration and Congress for America’s growing aging population and health equity goals starts with making investments in the country’s innovation ecosystem that will be essential in the next decade of aging.

Ask those making the decisions about investing in innovation, and they will tell you that undermining IP and price controls has a very substantial impact. If we want that innovation, the Biden administration and those on The Hill have to send the right policy signals, which, ironically, are opposite of the ones now being conveyed.

Source: The Hill

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.

New Report From the Global Coalition on Aging Highlights the Connection Between Adult Immunization and Economic Health in Aging APEC Region

As leaders from across the Asia-Pacific Economic Cooperation (APEC) region convene in San Francisco over the next week, a new report from the Global Coalition on Aging (GCOA) points to investments in healthy aging as a growing economic imperative amid the region’s changing demographics. According to the new report, programs that keep populations healthy, active, and productive – like adult immunization – are increasingly becoming a prerequisite for economic stability and growth.